The promise of stereotactic body radiation therapy in a new era of oncology

Frontiers of Radiation Therapy and Oncology

Volumn 40, Issue , 2007, Pages 340-351

  Kavanagh, B D ^a,b   Kelly, K ^a   Kane, M ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b Anschutz Cancer Pavilion ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; HUMAN; INSTRUMENTATION; METHODOLOGY; NEOPLASM; RADIATION DOSE; RADIOSURGERY;

HUMANS; NEOPLASMS; RADIOSURGERY; RADIOTHERAPY DOSAGE;

EID: 34547495577     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/0000106045     Document Type: Conference Paper

References (25)

1. Lax I, Blomgren H, Naslund I, Svanstrom R: Stereotactic radiotherapy of extracranial targets. Z Med Phys 1994;4:112-113.
2. Leksell L: The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 1951;102:316-319.
3. Blomgren H, Lax I, Naslund I, Svanstrom R: Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Acta Oncol 1995;34:861-870.
4. Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Hoss A, Schlegel W, Wannenmacher MF: Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001;19:164-70.
5. Wulf J, Hadinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M: Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001;177:645-655.
6. Uematsu M, Shioda A, Tahara K, Fukui T, Yamamoto F, Tsumatori G, Ozeki Y, Aoki T, Watanabe M, Kusano S: Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer 1998;82:1062-1070.
7. Shirato, H, Shimizu, S, Tadashi, S, Nishioka T, Miyasaka, K: Real time tumour-tracking radio-therapy. Lancet 1999;353:1331-1332.
8. Nagata Y, Negoro Y, Aoki T, Mizowaki T, Takayama K, Kokubo M, Araki N, Mitsumori M, Sasai K, Shibamoto Y, Koga S, Yano S, Hiraoka M: Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2002;52: 1041-1046.
9. Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, Williams M: Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946-1955.
10. Cardinale RM, Wu Q, Benedict SH, Kavanagh BD, Bump E, Mohan R: Determining the optimal block margin on the planning target volume for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 1999;45:515-520.
11. Timmerman RD, Kavanagh BD: Stereotactic body radiation therapy. Curr Probl Cancer 2005; 29:120-157.
12. Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, Welsh J, Mehta M, Larson DA, Janjan NA; American Society for Therapeutic Radiology and Oncology; American College of Radiology: American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation, therapy. Int J Radiat Oncol Biol Phys 2004;60:1026-1032.
13. Kavanagh BD, Timmerman RD, Benedict SH, Wu Q, Schefter TE, Stuhr K, McCourt S, New-man F, Cardinale RM, Gaspar LE: How should we describe the radiobiologic effect of extracranial stereotactic radiosurgery: equivalent uniform dose or tumor control, probability? Med Phys 2003;30:321-324.
14. Timmerman RD, Lohr F: Normal tissue dose constraints applied in lung stereotactic body radiation therapy; in Kavanagh BD, Timmerman RD (eds): Stereotactic Body Radiation. Therapy. Philadelphia, Lippincott, Williams & Wilkins, 2005.
15. Schefier TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005;62:1371-1378.
16. Yaes RJ, Kalend A: Local stem cell depletion model for radiation myelitis. Int J Radiat Oncol Biol Phys 1988;14:1247-1259.
17. Fowler JF, Tome WA, Welsh JS: On the estimation of required doses in. stereotactic body radiation, therapy; in Kavanagh BD, Timmerman RD (eds): Stereotactic Body Radiation Therapy. Philadelphia, Lippincott, Williams & Wilkins, 2005.
18. Brenner DJ: Hypofractionadon for prostate cancer radiotherapy - What are the issues? Int J Radiat Oncol Biol Phys 2003;57:912-914.
19. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ: What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003;56:1093-1104.
20. Guerrero M, Li X: Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 2004;49: 4825-4835.
21. Benedict SH, Lin PS, Zwicker RD, Huang DT, Schmidt-Ullrich RK: The biological effectiveness of intermittent irradiation as a function of overall treatment time: development of correction factors for linac-based stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 1997:37:765-769.
22. Gompertz B: On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Phil Trans R Soc Lond B Biol Sci 1825; 123:513-585.
23. Norton L, Simon R, Brereton HD, Bogden AE: Predicting the course of Gompertzian growth. Nature 1976;264:542-545.
24. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-1.69.
25. Fornier M, Norton L: Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res 2005;7:64-69.